It may be time to reset expectations on when we’ll get a Covid-19 vaccine
A host of factors appear to be adding up to a slippage in the estimates of when vaccine will be ready to be deployed.
A host of factors appear to be adding up to a slippage in the estimates of when vaccine will be ready to be deployed.
Eli Lilly agreed to acquire a manufacturing facility in Wisconsin from Nexus Pharmaceuticals to produce injectable medicines amid shortages of Mounjaro and Zepbound.
Biogen CEO Chris Viehbacher has been praised for reducing operating expenses. A return to revenue growth is still on the to-do list, however.
Donald Trump’s health care priorities remain fuzzy. But one thing is certain: A second Trump administration would put its own stamp on a host of…
The Joint Commission and the National Committee for Quality Assurance will launch updated accreditation programs for telehealth providers.
Easily a decade can pass before someone with a complex chronic condition gets a proper diagnosis. New telehealth companies aim to shorten that time and…
Gene therapies represent an evidence problem. Because they are just beginning to be used, little long-term data exists on their effectiveness and downstream risks.
The CIA’s mind-control projects in the 1950s involved some university psychiatrists, and often involved experimentation on vulnerable people.
Confusion over Makena, a controversial failed preterm delivery drug, caused some pregnant women to receive an untested treatment.
In a scientific first, researchers have used CRISPR base editing to treat liver disease in fetal monkeys.
Of 100 hospitals across 50 states surveyed by STAT about changes in maternal care after overturning of Roe v. Wade, only six agreed to speak.